📰 Recursion Pharma News
Page 2 - Recursion Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recursion Pharma. Real-time updates on events, politics, business and more.
July 13, 2023
While relatively modest in size, the investment from Nvidia could help prove Recursion’s datasets give discovery platforms a speed-to-clinic edge.
June 8, 2023
"TechBio" company Recursion Pharma has entered agreements to acquire AI/ML company Cyclica for $40 million and Valence for $47.5 million.
October 17, 2022
/PRNewswire/ -- Targeted therapies specifically attach to and hinder cancer-causing proteins, but cancer cells can quickly evolve to thwart their action. A...
October 17, 2022
NEW YORK, Oct. 17, 2022 /PRNewswire/ -- Targeted therapies specifically attach to and hinder cancer-causing proteins, but cancer cells can quickly...
May 11, 2021
Prototype Shows Promise As Approach to Countering Pancreatic Cancer News provided by Share this article Share this article NEW YORK, May 11, 2021 /PRNewswire/ -- A research team has designed a molecule with potential to interfere in a new way with altered proteins that cause abnormal growth in 35 percent of pancreatic cancers. Published online in Nature Communications on May 11, a new study found that a molecule called a monobody clings to cancer-causing versions of the KRAS protein and keeps ...
April 13, 2021
Recursion Pharmaceuticals has set terms for a major $306 million IPO as the artificial intelligence biotech eyes a $3 billion valuation.